Overview of the impact of NK cell levels on HCT outcomes in children and adults
| Reference . | Platform . | Adult/pediatric . | Outcome . | No. patients . | Type of study . |
|---|---|---|---|---|---|
| Mushtaq et al53 | All | Adult, pediatrics | Higher early NK cell number improves 2-year OS | 1785 patients from 21 studies. Reconstitution | Meta-analysis |
| Minculescu et al63 | T-cell replete | Adult | >150 NK cells per μL at day +30 improves OS | 298, single center | Retrospective |
| Troullioud Lucas et al21 | All | Pediatric, young adults | No association found between NK cell IR and outcomes | 503, multicenter | Retrospective |
| Cui et al464 | T-cell replete | Pediatric | >111 NK cells per μL at day +30 improves NRM | 122, single center | Retrospective |
| McCurdy et al65 | Haplo PTCy vs MSD/MUD | Adult | >50.5 cells per μL at day +28 improves OS and PFS | 145, single center | Prospective |
| Nguyen et al66 | CB, RIC | Adult | Higher CD16+ NK reduce TRM | 79, multicenter | Prospective |
| Kim et al67 | All | Adult | Lower (206.4 cells per mL vs 310.1 cells per μL) at day +30 and 90 days (147.6 cells per μL vs 403.0 cells per mL) associated with increased aGVHD. NKof >177 cells per μL at day +30 improves OS and PFS | 70, single center | Retrospective |
| Cui et al64 | All | Pediatric | NK of >111 cells per μL at day +30 and higher counts at day +60 improves 3-y OS, reduces RFS and NRM and aGVHD | 122, single center | Prospective |
| De Koning et al69 | T-cell repleted | Pediatric | Positive correlation between innate immunity and CD4+ T-cell recovery (either monocytes of >0.89 × 109/L and/or neutrophils >4.2 × 109/L and/or NK cells of >0.34 × 109/L within day +50) | 205, single center | Retrospective |
| Troullioud Lucas et al21 | BM, PBSC, ex vivo TCD, CB | Pediatric, young adult | No correlation between NK and survival | 503, multicenter | Retrospective |
| Reference . | Platform . | Adult/pediatric . | Outcome . | No. patients . | Type of study . |
|---|---|---|---|---|---|
| Mushtaq et al53 | All | Adult, pediatrics | Higher early NK cell number improves 2-year OS | 1785 patients from 21 studies. Reconstitution | Meta-analysis |
| Minculescu et al63 | T-cell replete | Adult | >150 NK cells per μL at day +30 improves OS | 298, single center | Retrospective |
| Troullioud Lucas et al21 | All | Pediatric, young adults | No association found between NK cell IR and outcomes | 503, multicenter | Retrospective |
| Cui et al464 | T-cell replete | Pediatric | >111 NK cells per μL at day +30 improves NRM | 122, single center | Retrospective |
| McCurdy et al65 | Haplo PTCy vs MSD/MUD | Adult | >50.5 cells per μL at day +28 improves OS and PFS | 145, single center | Prospective |
| Nguyen et al66 | CB, RIC | Adult | Higher CD16+ NK reduce TRM | 79, multicenter | Prospective |
| Kim et al67 | All | Adult | Lower (206.4 cells per mL vs 310.1 cells per μL) at day +30 and 90 days (147.6 cells per μL vs 403.0 cells per mL) associated with increased aGVHD. NKof >177 cells per μL at day +30 improves OS and PFS | 70, single center | Retrospective |
| Cui et al64 | All | Pediatric | NK of >111 cells per μL at day +30 and higher counts at day +60 improves 3-y OS, reduces RFS and NRM and aGVHD | 122, single center | Prospective |
| De Koning et al69 | T-cell repleted | Pediatric | Positive correlation between innate immunity and CD4+ T-cell recovery (either monocytes of >0.89 × 109/L and/or neutrophils >4.2 × 109/L and/or NK cells of >0.34 × 109/L within day +50) | 205, single center | Retrospective |
| Troullioud Lucas et al21 | BM, PBSC, ex vivo TCD, CB | Pediatric, young adult | No correlation between NK and survival | 503, multicenter | Retrospective |
haplo, haploidentical transplant; MSD, matched sibling donor; MUD, matched unrelated donor; PFS, progression-free survival; RFS, relapse-free survivale; RIC, reduced intensity conditioning regimen.